PanTher Therapeutics develops a polymer-based drug delivery system that enables high-dose, localized chemotherapy directly at tumor sites, significantly increasing drug concentration while minimizing systemic exposure. This approach addresses the limitations of traditional chemotherapy by providing continuous therapeutic levels over extended durations, enhancing treatment efficacy with reduced side effects.
Funding
Funding not disclosed
MIFounders
Product
Problem
Systemic chemotherapy for cancer often results in dose-limiting toxicities, restricting the amount of drug that can reach the tumor and limiting its effectiveness. Traditional methods may not provide sustained therapeutic drug levels at the tumor site, and can expose healthy tissues to harmful side effects.
Solution
PanTher Therapeutics is developing a polymer-based drug delivery platform, Sagittari, that enables localized, high-dose chemotherapy directly at the tumor site. This approach allows for significantly increased drug concentrations at the tumor while minimizing systemic exposure, leading to improved efficacy and reduced side effects. The platform is designed to provide continuous therapeutic drug levels over extended durations, such as weeks or months, enhancing treatment outcomes. The drug products are engineered with physical attributes that allow them to be readily used with established interventional oncology procedures.
Target Audience
The primary target audience includes oncologists and interventional radiologists treating solid tumors, as well as hospitals and cancer centers seeking to improve local drug delivery.
Features
- Sagittari platform enables the creation of drug products optimized for dose and duration.
- Polymer-based drug product administers drugs at an optimal dose over the desired duration of treatment.
- Drug product is designed with physical attributes that allow it to be readily used with established interventional oncology procedures.
- PTM-101, the lead product candidate, is in clinical development for the treatment of pancreatic cancer.
- Over 100 times increase in drug concentration at the tumor site compared to systemic administration.
- Limited, if any, systemic exposure which enables favorable tolerability.
- Continuous release of therapeutic levels of drug at the tumor site over a significantly extended duration of treatment (weeks or months).